Clinuvel Pharmaceuticals is a biopharmaceutical company engaged in the development of its drug candidate SCENESSE® (afamelanotide 16mg) for the treatment of a range of severe skin disorders. SCENESSE®, a drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the U.S. and Europe and has been approved by the European Commission for treating adults with EPP. Co.'s products aims at preventing the symptoms of skin diseases related to the exposure to harmful Ultraviolet radiation and at repigmentation of the skin due to a number of depigmentation disorders. Co. has operations in Europe, the U.S. and Singapore.
Research suggests that directors know their companies better than the market. For many investors it is intuitive that following the trading patterns of directors and other company insiders can lead to successful investing. They often have detailed knowledge about their companies and generally know when the shares are incorrectly valued. However, that is not always true and with large numbers of trades reported every day on exchanges around the world, it is difficult to know which to follow.
SmartInsider provides valuable insight by supplementing and analysing reported transactions to achieve real insight with a focus on identifying the ‘Smart Insiders’ and highlighting the stand-out transactions they make. Our proven track-record and thirty year pedigree are backed by more recent statistical analysis of historical data.
Our service offers director dealing reports, company reports and monthly summaries with a fully interactive website for further research. We can also provide quant feeds and customised alerts to suit every need at the frequency preferred. SmartInsider covers all markets with a regulatory requirement to report insider activity, over 60,000 companies across 55 markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.